Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Genmab
iOnctura
Suzhou BlueHorse Therapeutics Co., Ltd.
Gruppo Oncologico del Nord-Ovest
Shanghai Juncell Therapeutics
Inhibrx Biosciences, Inc
Tesaro, Inc.
Toray Industries, Inc
Iovance Biotherapeutics, Inc.
Shanghai Junshi Bioscience Co., Ltd.
Thomas Jefferson University
ImmunityBio, Inc.
ImmunityBio, Inc.
Charite University, Berlin, Germany
Eli Lilly and Company
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Eastern Cooperative Oncology Group
Nektar Therapeutics
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Peking University Cancer Hospital & Institute
M.D. Anderson Cancer Center
University of Utah
Altor BioScience
Radboud University Medical Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
SWOG Cancer Research Network
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
California Pacific Medical Center Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
M.D. Anderson Cancer Center
Mayo Clinic
Scripps Health
National Cancer Institute (NCI)
Point Therapeutics
Dermatologic Cooperative Oncology Group